More on RVMD

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-46.0% Growth)
- Ratings (9.6 Score)

Upcoming Events

- Earnings (11/11/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Revolution Medicines (NQ:RVMD)
Delayed: 177.96 -11.3 (5.97%)
Prev. Close $189.26  
Open$188.86 
52 Wk High$ 
52 Wk Low$ 
Day High$189.68 
Day Low$175.91 
P/E N/A  
EPS$ 
Volume2,973,858 

Friends, Peers and Foes (?): MRK, ABBV, ERAS, ONC, EYPT (more...)

Oct 16, 2026 07:54 AM Guggenheim Reiterates Buy Rating on Revolution (RVMD)
Oct 16, 2026 06:23 AM Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings
Oct 16, 2026 02:51 AM William Blair Starts Revolution (RVMD) at Outperform
Oct 15, 2026 09:46 AM Revolution Medicines' daraxonrasib gets positive EU panel opinion
Oct 15, 2026 09:45 AM Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
Oct 14, 2026 08:57 AM Revolution (RVMD) PT Raised to $260 at RBC Capital
Oct 13, 2026 04:32 PM Form 8-K Revolution Medicines, For: Oct 08
Oct 8, 2026 08:27 AM Revolution (RVMD) PT Raised to $259 at RBC Capital
Oct 7, 2026 07:14 AM Revolution (RVMD) PT Raised to $240 at Truist Securities
Oct 5, 2026 08:01 AM Revolution Medicines starts Phase 3 trial of drug combo for pancreatic cancer
View All Articles

Entities mentioned with RVMD

View All Entities